All In MedTech

FDA Clearance Tracker · P990023-S013

CELLUGEL OPHTHALMIC VISCOSURGICAL DEVICE (OVD)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 18, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 18, 2016

Approved

Time to decision

301 days

Received Apr 23, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990023-S013
Device name
CELLUGEL OPHTHALMIC VISCOSURGICAL DEVICE (OVD)
Applicant location
Fort Worth, TX
Received
Apr 23, 2015
Decided
Feb 18, 2016
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990023

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

Approval for an alternate packaging configuration (syringe, rubber tip cap, pouch), change in the release specification for pH, and change in the release and stability specification for osmolality.

Source documents

Other decisions for Alcon Laboratories

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.